- Home
- FTHY vs AKBA Comparison
FTHY vs AKBA Comparison
Compare FTHY & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- AKBA
- Stock Information
- Founded
- FTHY 2020
- AKBA 2007
- Country
- FTHY United States
- AKBA United States
- Employees
- FTHY N/A
- AKBA N/A
- Industry
- FTHY Investment Managers
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- FTHY Finance
- AKBA Health Care
- Exchange
- FTHY Nasdaq
- AKBA Nasdaq
- Market Cap
- FTHY 500.1M
- AKBA 559.0M
- IPO Year
- FTHY N/A
- AKBA 2014
- Fundamental
- Price
- FTHY $14.18
- AKBA $2.55
- Analyst Decision
- FTHY
- AKBA Strong Buy
- Analyst Count
- FTHY 0
- AKBA 4
- Target Price
- FTHY N/A
- AKBA $6.63
- AVG Volume (30 Days)
- FTHY 176.7K
- AKBA 3.7M
- Earning Date
- FTHY 01-01-0001
- AKBA 05-08-2025
- Dividend Yield
- FTHY 10.93%
- AKBA N/A
- EPS Growth
- FTHY N/A
- AKBA N/A
- EPS
- FTHY N/A
- AKBA N/A
- Revenue
- FTHY N/A
- AKBA $184,909,000.00
- Revenue This Year
- FTHY N/A
- AKBA $22.50
- Revenue Next Year
- FTHY N/A
- AKBA $43.23
- P/E Ratio
- FTHY N/A
- AKBA N/A
- Revenue Growth
- FTHY N/A
- AKBA N/A
- 52 Week Low
- FTHY $12.66
- AKBA $0.80
- 52 Week High
- FTHY $14.74
- AKBA $2.89
- Technical
- Relative Strength Index (RSI)
- FTHY 54.35
- AKBA 65.48
- Support Level
- FTHY $14.02
- AKBA $2.25
- Resistance Level
- FTHY $14.30
- AKBA $2.90
- Average True Range (ATR)
- FTHY 0.14
- AKBA 0.14
- MACD
- FTHY 0.03
- AKBA 0.03
- Stochastic Oscillator
- FTHY 69.57
- AKBA 58.33
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.